EA201100653A1 - Лиганды, связывающиеся с интерлейкином-13 (il-13) - Google Patents

Лиганды, связывающиеся с интерлейкином-13 (il-13)

Info

Publication number
EA201100653A1
EA201100653A1 EA201100653A EA201100653A EA201100653A1 EA 201100653 A1 EA201100653 A1 EA 201100653A1 EA 201100653 A EA201100653 A EA 201100653A EA 201100653 A EA201100653 A EA 201100653A EA 201100653 A1 EA201100653 A1 EA 201100653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ligands
interlaykin
interleukin
disclosed
ligands connecting
Prior art date
Application number
EA201100653A
Other languages
English (en)
Inventor
Рудольф М Т Де Вилдт
Инуша Де Сильва
Милан Овека
Original Assignee
Глаксо Груп Лимитед
Домантис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед, Домантис Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201100653A1 publication Critical patent/EA201100653A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Раскрыты лиганды, имеющие специфичность связывания в отношении интерлейкина-13 (IL-13) или в отношении интерлейкина-4 (IL-4) и IL-13. Также раскрыты способы применения этих лигандов. В частности, описано применение этих лигандов для лечения IL-13-опосредованных состояний, таких как легочные состояния, например аллергическая астма. Лиганды имеют активную кинетику связывания с IL-13. Описаны лиганды, перекрестно-реактивные в отношении человеческого IL-13 и IL-13 одного или более чем одного примата. Лиганды хорошо экспрессируются в прокариотических клетках.
EA201100653A 2008-11-26 2008-12-17 Лиганды, связывающиеся с интерлейкином-13 (il-13) EA201100653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11801308P 2008-11-26 2008-11-26
PCT/EP2008/067789 WO2010060486A1 (en) 2008-11-26 2008-12-17 Ligands that bind il-13

Publications (1)

Publication Number Publication Date
EA201100653A1 true EA201100653A1 (ru) 2011-12-30

Family

ID=40993100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100653A EA201100653A1 (ru) 2008-11-26 2008-12-17 Лиганды, связывающиеся с интерлейкином-13 (il-13)

Country Status (14)

Country Link
US (1) US20110236380A1 (ru)
EP (1) EP2358754A1 (ru)
JP (1) JP2012509658A (ru)
KR (1) KR20110092328A (ru)
CN (1) CN102292351A (ru)
AU (1) AU2008364461A1 (ru)
BR (1) BRPI0823231A2 (ru)
CA (1) CA2744588A1 (ru)
EA (1) EA201100653A1 (ru)
IL (1) IL212812A0 (ru)
MX (1) MX2011005541A (ru)
SG (1) SG171733A1 (ru)
WO (1) WO2010060486A1 (ru)
ZA (1) ZA201103692B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33052B1 (fr) 2009-02-19 2012-02-01 Glaxo Group Ltd Variants de liaison anti-albumine sérique améliorés
AR075505A1 (es) 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
AR090339A1 (es) * 2012-03-27 2014-11-05 Genentech Inc Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CN113563478A (zh) 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308494B2 (en) * 2003-12-23 2010-03-18 Genentech, Inc. Novel anti-IL 13 antibodies and uses thereof
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
TW200938222A (en) * 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
BRPI0823231A2 (pt) 2015-06-16
US20110236380A1 (en) 2011-09-29
SG171733A1 (en) 2011-07-28
KR20110092328A (ko) 2011-08-17
WO2010060486A1 (en) 2010-06-03
MX2011005541A (es) 2011-09-21
ZA201103692B (en) 2012-10-31
AU2008364461A1 (en) 2010-06-03
JP2012509658A (ja) 2012-04-26
EP2358754A1 (en) 2011-08-24
IL212812A0 (en) 2011-07-31
CA2744588A1 (en) 2010-06-03
CN102292351A (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
MY162511A (en) Engineered anti-tslp antibody
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
EA201100653A1 (ru) Лиганды, связывающиеся с интерлейкином-13 (il-13)
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2009010092A (es) Anticuerpos anti ige apoptoticos.
WO2011150133A3 (en) Fibronectin based scaffold proteins having improved stability
EA201300323A1 (ru) Материалы и способы улучшения функции желудочно-кишечного тракта
MX2013003468A (es) Anticuerpos anti-cd48 y usos de los mismos.
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
WO2010067130A8 (en) P38 map kinase inhibitors
SG165322A1 (en) Engineered anti-il-23 antibodies
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP3722320A3 (en) Anti-complement c1s antibodies and uses thereof
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
WO2011163652A3 (en) Treatment of sanfilippo syndrome type b
MX2010001779A (es) Peptidos para vacunas.
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2010015929A3 (en) Uses of mesenchymal stem cells
MX341838B (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.